PT1082298E - 1alfa-hidroxi-25-eno-vitamina d seus analogos e seus usos - Google Patents

1alfa-hidroxi-25-eno-vitamina d seus analogos e seus usos

Info

Publication number
PT1082298E
PT1082298E PT99928357T PT99928357T PT1082298E PT 1082298 E PT1082298 E PT 1082298E PT 99928357 T PT99928357 T PT 99928357T PT 99928357 T PT99928357 T PT 99928357T PT 1082298 E PT1082298 E PT 1082298E
Authority
PT
Portugal
Prior art keywords
1alfa
vitamine
eno
analogs
hydroxy
Prior art date
Application number
PT99928357T
Other languages
English (en)
Inventor
Joyce C Knutson
Charles W Bishop
Stephen Strugnell
Original Assignee
Bone Care Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bone Care Int Inc filed Critical Bone Care Int Inc
Publication of PT1082298E publication Critical patent/PT1082298E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PT99928357T 1998-05-29 1999-05-28 1alfa-hidroxi-25-eno-vitamina d seus analogos e seus usos PT1082298E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/087,439 US5972917A (en) 1998-05-29 1998-05-29 1 α-hydroxy-25-ene-vitamin D, analogs and uses thereof

Publications (1)

Publication Number Publication Date
PT1082298E true PT1082298E (pt) 2004-03-31

Family

ID=22205199

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99928357T PT1082298E (pt) 1998-05-29 1999-05-28 1alfa-hidroxi-25-eno-vitamina d seus analogos e seus usos

Country Status (14)

Country Link
US (1) US5972917A (pt)
EP (1) EP1082298B1 (pt)
JP (1) JP2002516307A (pt)
CN (1) CN1238341C (pt)
AT (1) ATE253554T1 (pt)
AU (1) AU754211B2 (pt)
BR (1) BR9910672A (pt)
CA (1) CA2333270A1 (pt)
DE (1) DE69912598T2 (pt)
DK (1) DK1082298T3 (pt)
ES (1) ES2211107T3 (pt)
IL (1) IL139353A (pt)
PT (1) PT1082298E (pt)
WO (1) WO1999061418A2 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US20020183288A1 (en) * 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US6087350A (en) 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
AUPP405098A0 (en) * 1998-06-12 1998-07-02 Access Pharmaceuticals Australia Pty Limited Novel methods of preparation of vitamin b12 derivatives suitable for conjugation to pharmaceuticals
DE60024118T2 (de) * 1999-09-20 2006-07-27 Eli Lilly And Co., Indianapolis Verwendung einer parathyroidhormone zur reduktion des krebsrisikos
JP2004504295A (ja) * 2000-07-18 2004-02-12 ボーン　ケア　インターナショナル　インコーポレイテッド 安定化１α−ヒドロキシビタミンＤ
US7129230B2 (en) 2001-03-12 2006-10-31 Nestec S.A. Method and product for treating cancer in pets
US6465446B1 (en) * 2001-03-12 2002-10-15 John C. Dykstra Treatment of dermatitis by the topical application of Δ5-androstene-3β-ol-7,17 dione and metabolizable precursors thereof
KR20050044655A (ko) * 2001-12-03 2005-05-12 노바세아, 인크. 활성 비타민 ｄ 화합물을 함유하는 약제학적 조성물
EP1466900B1 (en) * 2001-12-26 2009-01-14 Hiroaki Takayama 2-substituted vitamin d derivatives
AU2003228365B2 (en) * 2002-03-29 2008-02-14 Wisconsin Alumni Research Foundation Method of synthesizing 1 alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
KR20050055784A (ko) * 2002-10-23 2005-06-13 레오 파마 에이/에스 비타민 디 유사체, 이 유사체를 포함하는 조성물 및 이들의용도
AU2003295773A1 (en) * 2002-11-21 2004-06-18 Novacea, Inc. Treatment of liver disease with active vitamin d compounds
JP2007501865A (ja) * 2003-06-11 2007-02-01 ノバセア インコーポレイティッド 放射線治療薬および放射線治療と併用した、活性ビタミンｄ化合物による癌の治療法
CA2528378A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
SG110107A1 (en) 2003-09-24 2005-04-28 Bioxell Spa Compound and use in treatment
US7214671B2 (en) * 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
US7713951B2 (en) * 2004-04-09 2010-05-11 Wisconsin Alumni Research Foundation 2-alkylidene-18,19-dinor-vitamin D compounds
WO2005117542A2 (en) * 2004-05-10 2005-12-15 Novacea, Inc. Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
US7094775B2 (en) * 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
WO2006113990A2 (en) * 2005-04-25 2006-11-02 Cytochroma Inc. LOW-CALCEMIC 16,23-DIENE 25-OXIME ANALOGS OF 1α ,25-DIHYDROXY VITAMIN D3
CN101277708B (zh) * 2005-10-06 2013-02-13 雀巢技术公司 用于改良免疫性的益生肠道球菌
US8318459B2 (en) 2011-02-17 2012-11-27 Purecircle Usa Glucosyl stevia composition
US9392799B2 (en) 2011-02-17 2016-07-19 Purecircle Sdn Bhd Glucosyl stevia composition
US9386797B2 (en) 2011-02-17 2016-07-12 Purecircle Sdn Bhd Glucosyl stevia composition
US9107436B2 (en) 2011-02-17 2015-08-18 Purecircle Sdn Bhd Glucosylated steviol glycoside as a flavor modifier
US8257948B1 (en) 2011-02-17 2012-09-04 Purecircle Usa Method of preparing alpha-glucosyl Stevia composition
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
KR101991692B1 (ko) 2009-01-27 2019-06-21 베르그 엘엘씨 화학요법과 연관된 부작용을 경감시키기 위한 비타민 ｄ３ 및 이의 유사물
EA201270226A1 (ru) 2009-08-14 2012-09-28 БЕРГ БАЙОСИСТЕМЗ, ЭлЭлСи Витамин d3 и его аналогии для лечения алопеции
EP4108668A1 (en) 2010-03-12 2022-12-28 PureCircle USA Inc. High-purity steviol glycosides
WO2011123476A1 (en) * 2010-03-29 2011-10-06 Cytochroma Inc. Methods and compositions for reducing parathyroid levels
US9510611B2 (en) 2010-12-13 2016-12-06 Purecircle Sdn Bhd Stevia composition to improve sweetness and flavor profile
BR112013014589B1 (pt) 2010-12-13 2019-04-02 Purecircle Usa Inc. Método para preparar uma composição de rebaudiosídeo d altamente solúvel
WO2014179737A2 (en) 2013-05-03 2014-11-06 The General Hospital Corporation Assays and methods of treatment relating to vitamin d insufficiency
WO2012094550A2 (en) 2011-01-07 2012-07-12 The General Hospital Corporation Assays and methods of treatment relating to vitamin d insufficiency
US9052308B2 (en) 2011-01-07 2015-06-09 The General Hospital Corporation Assays and methods of treatment relating to vitamin D insufficiency
BR112013020511B1 (pt) 2011-02-10 2018-05-22 Purecircle Usa Inc. Composição de rebaudiosida b e seu processo de produção, bem como composições de adoçante e de sabor, ingrediente alimentício, bebida e produto cosmético ou farmacêutico compreendendo a dita composição de rebaudiosida b
US9474296B2 (en) 2011-02-17 2016-10-25 Purecircle Sdn Bhd Glucosyl stevia composition
DE102011112532B4 (de) 2011-09-05 2019-03-21 Audi Ag Prüfeinrichtung und Verfahren zum Prüfen von Batteriezellen
EP2852296B1 (en) 2012-05-22 2021-12-15 PureCircle SDN BHD Process for producing a high-purity steviol glycoside
US9370527B2 (en) * 2012-12-28 2016-06-21 The Regents Of The University Of Michigan Amelioration of intestinal fibrosis and treatment of Crohn's disease
EP3003497B1 (en) 2013-05-29 2024-02-14 BPGbio, Inc. Preventing or mitigating chemotherapy induced alopecia using vitamin d

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4202829A (en) * 1978-01-05 1980-05-13 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4195027A (en) * 1978-01-16 1980-03-25 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4260549A (en) * 1979-05-21 1981-04-07 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4225596A (en) * 1978-10-13 1980-09-30 Wisconsin Alumni Research Foundation Method for treating calcium imbalance and improving calcium absorption in mammals
JPS5626820A (en) * 1979-08-10 1981-03-16 Chugai Pharmaceut Co Ltd Immunosuppressing agent
US4234495A (en) * 1979-09-10 1980-11-18 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxyvitamin D compounds from 1α-hydroxy-3,5-cyclovitamin D compounds
CA1160217A (en) * 1979-10-23 1984-01-10 Osamu Nishikawa Process for the preparation of active-type vitamin d.sub.3 compounds
JPS57149224A (en) * 1981-03-13 1982-09-14 Chugai Pharmaceut Co Ltd Tumor-suppressing agent
US4652405A (en) * 1981-08-28 1987-03-24 Hoffman-La Roche Inc. Synthesis of 1α,25-dihydroxy-24R-fluorocholecalciferol and 1α,25-dihydroxy-24S-fluorocholecalciferol
US4689180A (en) * 1984-01-30 1987-08-25 Wisconsin Alumni Research Foundation 1α,25-dihydroxy-22Z-dehydroxyvitamin D compound
US4481198A (en) * 1984-02-13 1984-11-06 Wisconsin Alumni Research Foundation Vitamin D metabolism inhibitor
US4554106A (en) * 1984-11-01 1985-11-19 Wisconsin Alumni Research Foundation Method for preparing 1α-hydroxyvitamin D compounds
US4555364A (en) * 1984-11-01 1985-11-26 Wisconsin Alumni Research Foundation Method for preparing 1-hydroxyvitamin D compounds
EP0184112B1 (en) * 1984-11-27 1990-05-09 Chugai Seiyaku Kabushiki Kaisha Novel vitamin d derivatives and process for producing the same
US4749710A (en) * 1985-05-01 1988-06-07 Hoffmann-La Roche Inc. Immunosuppressive agents
KR0144358B1 (ko) * 1988-04-21 1998-07-15 피. 라이달 크리스텐슨 비타민 d 동족체
US5250523A (en) * 1988-04-29 1993-10-05 Wisconsin Alumni Research Foundation Side chain unsaturated 1α-hydroxyvitanim D homologs
ATE90075T1 (de) * 1988-12-12 1993-06-15 Duphar Int Res Verfahren zur photochemischen umwandlung von tachysterol-derivaten in praevitamin d-derivate und von transvitamin d-derivaten in cisvitamin d- derivate.
US5098899A (en) * 1989-03-06 1992-03-24 Trustees Of Boston University Method for therapeutically treating psoriatic arthritis using vitamin D analogues and metabolites
CA1333616C (en) * 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
GB2229921B (en) * 1989-04-05 1992-12-16 Chugai Pharmaceutical Co Ltd Treatment for hyperparathyroidism with use of vitamin d derivatives
GB8915770D0 (en) * 1989-07-10 1989-08-31 Leo Pharm Prod Ltd Chemical compounds
AU652130B2 (en) * 1989-09-25 1994-08-18 University Of Utah Research Foundation Use of steroid hormones in compositions for inducing T cell lymphokine production
US5562910A (en) * 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
US5518725A (en) * 1989-09-25 1996-05-21 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US5260290A (en) * 1990-02-14 1993-11-09 Wisconsin Alumni Research Foundation Homologated vitamin D2 compounds and the corresponding 1α-hydroxylated derivatives
GB9007236D0 (en) * 1990-03-30 1990-05-30 Leo Pharm Prod Ltd Chemical compounds
DK0454204T3 (da) * 1990-04-27 1995-08-28 Duphar Int Res Fremgangsmåde til fotokemisk isomerisering af organiske forbindelser og indflydelse herpå af en fotosensibilisator
EP0558119B1 (en) * 1992-02-27 2000-01-05 Duphar International Research B.V Method of preparating 9beta, 10alpha-5,7-diene steroids
DE4220757A1 (de) * 1992-06-24 1994-01-05 Schering Ag Derivate in der Vitamin D-Reihe mit Modifikationen in der 20-Position, Verfahren zu ihrer Herstellung, Zwischenprodukte für dieses Verfahren, diese Derivate enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
GB9220439D0 (en) * 1992-09-28 1992-11-11 Leo Pharm Prod Ltd Chemical compounds
US5753638A (en) * 1992-10-07 1998-05-19 Hoffmann-La Roche Inc. Method of treating hyperproliferative skin disease with Vitamin D3 fluorinated analogs
GB9223061D0 (en) * 1992-11-04 1992-12-16 Leo Pharm Prod Ltd Chemical compounds
US5449668A (en) * 1993-06-04 1995-09-12 Duphar International Research B.V. Vitamin D compounds and method of preparing these compounds
US5665387A (en) * 1994-09-01 1997-09-09 K.U. Leuven Research & Development Methods and compositions for primary and secondary prevention of autoimmune diabetes
US5559107A (en) * 1994-10-20 1996-09-24 Gates; Stephen Regulation of immune response
DE59604498D1 (de) * 1995-06-14 2000-03-30 Schering Ag Vitamin d-derivate mit substituenten an c-25, verfahren zu ihrer herstellung, zwischenprodukte und die verwendung zur herstellung von arzneimitteln
GB9524812D0 (en) * 1995-12-05 1996-02-07 Leo Pharm Prod Ltd Chemical compounds
US5716946A (en) * 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment

Also Published As

Publication number Publication date
CN1238341C (zh) 2006-01-25
IL139353A0 (en) 2001-11-25
DK1082298T3 (da) 2004-02-16
JP2002516307A (ja) 2002-06-04
AU4544599A (en) 1999-12-13
CN1303368A (zh) 2001-07-11
AU754211B2 (en) 2002-11-07
ES2211107T3 (es) 2004-07-01
DE69912598D1 (de) 2003-12-11
WO1999061418A2 (en) 1999-12-02
BR9910672A (pt) 2001-01-30
ATE253554T1 (de) 2003-11-15
EP1082298A2 (en) 2001-03-14
CA2333270A1 (en) 1999-12-02
WO1999061418A3 (en) 2000-03-23
EP1082298B1 (en) 2003-11-05
US5972917A (en) 1999-10-26
IL139353A (en) 2005-08-31
DE69912598T2 (de) 2004-09-23

Similar Documents

Publication Publication Date Title
PT1082298E (pt) 1alfa-hidroxi-25-eno-vitamina d seus analogos e seus usos
DE69911596D1 (de) 24-hydroxy vitamin d, deren analogen und verwendungen
DE69200675D1 (de) Verwendung von Droloxifen bei der Behandlung von Knochenerkrankungen.
PT1404324E (pt) Formas de dosagem administradas oralmente de pró-fármacos análogas de gaba tendo toxicidade reduzida
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
ATE281085T1 (de) Nahrungsergänzung zur behandlung von makula degeneration
BR0214838A (pt) Composição para promoção de crescimento ósseo e manutenção da saúde óssea
MX171177B (es) Composicion para desinfectar sustratos
ES270607Y (es) Implante de huesos, especialmente protesis para la articulacion de la cadera.
DE69905170T2 (de) Thiazolopyrimidinderivate
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
PT2009025E (pt) Método de inibição da actividade dos osteoclastos
IL103277A (en) N-alkyl-3-phenyl-3- (2-alkylthiophenoxy) propylamines and pharmaceutical compositions containing them
MXPA02012857A (es) Uso de una formulacion elaborada de o que contiene al menos un suero de leche dismilado.
ATE269085T1 (de) Verwendung von diltiazem zur behandlung von pathologien der netzhaut
NO20006699D0 (no) Forbindelser med veksthormonfrigjörende egenskaper
MXPA03008039A (es) Polipeptidos de serpina humanos.
ZA966953B (en) Pharmaceutical composition.
BR0307021A (pt) Uso de alquilfosfocolinas no tratamento preventivo de doenças de protozoários
NO20012169D0 (no) Forbindelser med veksthormonfrigjörende egenskaper
ES2192219T3 (es) Composiciones para la prevencion y tratamiento de trastornos urogenitales, que contienen bismuto.
IT212564Z2 (it) Semibusto anatomico sanitario ortopedico per la regione lombare.
UY26641A1 (es) Aril- y heteroarilsulfonatos